Navigation Links
MannKind Corporation to Host Webcast Analyst Day September 16, 2008
Date:9/11/2008

Company To Review Data from First Pivotal Phase 3 Clinical Trial

VALENCIA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced that it will host an analyst day for the investment community to review clinical results from Phase 3 and other clinical trials of the company's Technosphere(R) Insulin System. The meeting will take place on Tuesday, September 16, 2008 from 9 a.m. to 11 a.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit the MannKind Corporation web site at http://www.mannkindcorp.com.

Mr. Al Mann and other members of MannKind's management will review the Phase 3 data, and the meeting will also feature John ("Jack") E. Gerich, M.D., a world renowned diabetologist and expert in the physiology of diabetes and glucose metabolism. Dr. Gerich is professor of medicine and physiology and director of the clinical research center at the University of Rochester School of Medicine.

About the Technosphere(R) Insulin System

MannKind's investigational inhaled insulin product consists of its proprietary Technosphere(R) particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using MannKind's proprietary MedTone inhaler. A long sought-after goal in the treatment of diabetes has been to produce a profile of insulin levels in the bloodstream that closely mimics the normal human physiologic insulin response. In clinical studies to date, the Technosphere(R) Insulin System has been consistently observed to produce peak insulin levels within 12-14 minutes of inhalation, which approximates the early insulin secretion normally seen in healthy individuals following the beginning of a meal. MannKind believes that the ability to produce a better approximation of normal insulin physiology translates into better glucose control, thereby giving this investigational product potential clinical and commercial advantages.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes Technosphere(R) Insulin, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MannKind Announces New $350 Million Credit Facility
2. MannKind to Present at Upcoming Conferences
3. MannKind Corporation Reports Third Quarter Financial Results
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind to Present at the Cowen and Company Healthcare Conference
6. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
7. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
8. Brooke Franchise Corporation Announces Selected July Results
9. MedThink Communications Retained by NanoBio Corporation
10. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
11. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology: